Search

Your search keyword '"Falge, C"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Falge, C" Remove constraint Author: "Falge, C"
45 results on '"Falge, C"'

Search Results

1. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

5. Kollaborative Online-Forschung in Zeiten von COVID-19: Eine Community-Forschung zu Online-Gesundheitsinformationen im Kontext diversitätssensibler Aspekte

6. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

7. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

9. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

10. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

11. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633

12. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632

13. Optimization of imatinib therapy by combination. Final results of the pilot phase of the randomized German CML Study IV: V279

14. OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION. DESIGNED FIRST INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV: V54

15. Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) in the imatinib era: Evaluation of its impact within a subgroup of the German CML Study IV: V56

17. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

18. Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

19. ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV

20. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

22. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

23. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

25. Multizentrische prospektive kontrollierte Studie zur Therapie der chronisch myeloischen Leukämie. Vergleich von Busulfan, Hydroxyurea und Interferon alpha (Stand April 1990)

27. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group

28. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

29. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

30. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

33. Randomized Comparison of Interferon-α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia

34. Strategies for change among institutional and civil society actors

35. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

36. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

37. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

38. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

39. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

40. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

41. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

42. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

43. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

44. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.

Catalog

Books, media, physical & digital resources